Dulaglutide: A Review in Type 2 Diabetes

Abstract

Dulaglutide (Trulicity™) is a once-weekly subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2DM). In randomized controlled trials in patients with T2DM, dulaglutide… (More)
DOI: 10.1007/s40259-015-0143-4

2 Figures and Tables

Topics

  • Presentations referencing similar topics